Yidu Technology (02158) has repurchased 8 times since December, with a total investment of about HK$14 million

The Zhitong Finance App learned that on December 16, Yidu Technology (02158) issued an announcement showing that about 640,000 shares were repurchased at a price of HK$4.94 per share on the same day, with a repurchase amount of about HK$3.2 million. Since December, the company has repurchased 8 times, with a total repurchase of about 2.75 million shares, with a total amount of about HK$14 million.

Behind the intensive buybacks is the company's firm recognition of its own value, which also relies on the dual support of performance improvement and business expansion. Yidu Technology achieved key breakthroughs in profit quality and operational efficiency in its 2026 interim results. The current business adjusted EBITDA of about 54 million yuan, double that of the same period last year, and is almost break-even at the accounting statement level.

Everbright Securities pointed out in a follow-up report that the company has recently made many advances in implementing AI medical innovation, including deep participation in the Beijing National Artificial Intelligence Application Pilot Base in the medical field, winning the bid for Phase III clinical research projects, and adding “welfare insurance” services in Hebei and Guangzhou. According to the report, its medical model has initially constructed a closed loop of “data - algorithm - scenario” to promote the continuous implementation of the business in multiple scenarios.

Also worth noting is that Ms. Gong Rujing, founder and chairman of the company, was recently hired as a member of the Advisory Committee of the Digital Medicine Research Institute of the City University of Hong Kong. She will act as a key bridge between industry practice and academic research, promote industry-university-research integration to a higher level and more substantial stage, and inject new momentum into the construction of the industry's innovation ecosystem.